189 related articles for article (PubMed ID: 34242404)
1. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients.
Iftimi AA; Rodríguez-Bernal CL; Peiró S; Bonanad S; Ferrero-Gregori A; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
Clin Pharmacol Ther; 2022 Jan; 111(1):200-208. PubMed ID: 34242404
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants are associated with lower risk of dementia in patients with atrial fibrillation.
Sagris D; Ntaios G; Buckley BJR; Harrison SL; Underhill P; Lane DA; Lip GYH
Eur J Intern Med; 2024 Mar; 121():114-120. PubMed ID: 37914656
[TBL] [Abstract][Full Text] [Related]
6. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation.
Abrahami D; Renoux C; Yin H; Fournier JP; Azoulay L
Thromb Haemost; 2020 Oct; 120(10):1384-1394. PubMed ID: 32717756
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
[TBL] [Abstract][Full Text] [Related]
8. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
Renoux C; Coulombe J; Suissa S
BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
10. Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists.
He N; Dell'Aniello S; Zhai S; Suissa S; Renoux C
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):389-397. PubMed ID: 32722764
[TBL] [Abstract][Full Text] [Related]
11. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
Stolk LM; de Vries F; Ebbelaar C; de Boer A; Schalekamp T; Souverein P; Ten Cate-Hoek A; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1835-1843. PubMed ID: 28326589
[TBL] [Abstract][Full Text] [Related]
12. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.
Douros A; Renoux C; Yin H; Filion KB; Suissa S; Azoulay L
Am J Med; 2019 Feb; 132(2):191-199.e12. PubMed ID: 30691551
[TBL] [Abstract][Full Text] [Related]
13. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
[TBL] [Abstract][Full Text] [Related]
14. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
Seiffge DJ; Paciaroni M; Wilson D; Koga M; Macha K; Cappellari M; Schaedelin S; Shakeshaft C; Takagi M; Tsivgoulis G; Bonetti B; Kallmünzer B; Arihiro S; Alberti A; Polymeris AA; Ambler G; Yoshimura S; Venti M; Bonati LH; Muir KW; Yamagami H; Thilemann S; Altavilla R; Peters N; Inoue M; Bobinger T; Agnelli G; Brown MM; Sato S; Acciarresi M; Jager HR; Bovi P; Schwab S; Lyrer P; Caso V; Toyoda K; Werring DJ; Engelter ST; De Marchis GM;
Ann Neurol; 2019 Jun; 85(6):823-834. PubMed ID: 30980560
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.
Sakai T; Motoki H; Fuchida A; Takeuchi T; Otagiri K; Kanai M; Kimura K; Minamisawa M; Yoshie K; Saigusa T; Ebisawa S; Okada A; Kitabayashi H; Kuwahara K
Heart Vessels; 2022 Jul; 37(7):1232-1241. PubMed ID: 35064298
[TBL] [Abstract][Full Text] [Related]
17. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
[TBL] [Abstract][Full Text] [Related]
18. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
[TBL] [Abstract][Full Text] [Related]
19. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.
Binding C; Bjerring Olesen J; Abrahamsen B; Staerk L; Gislason G; Nissen Bonde A
J Am Coll Cardiol; 2019 Oct; 74(17):2150-2158. PubMed ID: 31648707
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
